Introduzca los términos de búsqueda.

Web Fuerteventura Digital Envíe el formulario de búsqueda

 •INICIO  •HOME

Viajes a Fuerteventura

Pincha Para Ver los Pronosticos de Maldini de la Jornada

LAS NOTICIAS DE CANARIAS,ESPAÑA *
E INTERNACIONAL CON SECCIONES
COMO VIDEOS,Y MAS EN NOTICANARIAS

1 Julio, 2009 

Zacks Analyst Blog Highlights: Cytori Therapeutics, Luminex Corp., Bank of NY Mellon, First Advantage Corporation and First American Corporation CHICAGO--(BUSINESS WIRE)--Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Cytori Therapeutics (Nasdaq: CYTX), Luminex Corp. (Nasdaq: LMNX), Bank of NY Mellon (NYSE: BK), First Advantage Corporation (Nasdaq: FADV) and First American Corporation (NYSE: FAF). Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579 Here are highlights from Monday’s Analyst Blog: Cytori's IP and Cash Position Solid Two concerns for investors in Cytori Therapeutics (Nasdaq: CYTX) have been the intellectual property (IP) and the cash position. We believe both are solid, and should not prohibit investment in the name at the current stock price. Intellectual property has been a concern for investors ever since the summer of 2008 when the U.S. District Court in California removed The University of California from USPTO # 6,777,231, a patient licensed from Cal to Cytori which covers isolated adipose-derived stem cells. However, since that time, management has vigorously worked to protect its ability to isolate adipose-derived stem cells and sell the Celution System. And despite the loss of the '231 patent at Cal, Cytori has half a dozen other active patents protecting the Celution System, which includes 5 different device components or reagents. Luminex - Expect Strong Growth in 2009 Luminex Corp. (Nasdaq: LMNX) posted revenue of $104.5 million in 2008, marking growth of 39% from 2007. Technology segment sales increased 34% to $83.6 million, while Assay segment sales grew 66% to $20.9 million. Through the first quarter 2009, Technology segment sales grew 13% to $21.1 million and Assay segment sales increased 2% to $4.5 million. Total revenue grew 11% in the first quarter to $25.6 million. Technology segment sales continue to be driven by growth in consumables and royalties. EPS came in at $0.08 in 2008 and $0.04 (adjusted for litigation expense) in the first quarter 2009, compared to ($0.47) and ($0.03) in the year-earlier periods, respectively. Gross margins increased by 240 basis points in the most recent quarter as the company's product mix shifted towards higher margin consumables and royalties. Expect Writedowns For Bank NY Mellon Profits for 2009 at Bank of NY Mellon (NYSE: BK) should reflect further writedowns from securitized mortgages that it still has on its books. Presently, BK has securitized mortgages totaling $3­4 billion on its books, representing approximately 2% of the company's balance sheet. Even though the company has seen the curtailment of its profits during this current crisis, it has posted profits and expects to remain profitable for 2009 overall. First Advantage Receives Buyout Offer Shares of First Advantage Corporation (Nasdaq: FADV) are trading higher today after the company received a buyout offer. First American Corporation (NYSE: FAF), which already owns 74% of the outstanding shares of First Advantage, is seeking to acquire the remaining 26% of the company that it does not control. The offer calls for First Advantage shareholders to receive 0.5375 shares of First American common stock for each share of First Advantage common stock owned. Based upon Friday's closing prices, the deal values First Advantage at $14.04 per share, for a premium of approximately 10%. Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=2649. About Zacks Equity Research Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term. Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons. Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=2677